Gates Open Research (Jan 2018)

Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa [version 2; referees: 2 approved]

  • Renee Heffron,
  • Kenneth Ngure,
  • Josephine Odoyo,
  • Nulu Bulya,
  • Edna Tindimwebwa,
  • Ting Hong,
  • Lara Kidoguchi,
  • Deborah Donnell,
  • Nelly R. Mugo,
  • Elizabeth A. Bukusi,
  • Elly Katabira,
  • Stephen Asiimwe,
  • Jennifer Morton,
  • Susan Morrison,
  • Harald Haugen,
  • Andrew Mujugira,
  • Jessica E. Haberer,
  • Norma C. Ware,
  • Monique A. Wyatt,
  • Mark A. Marzinke,
  • Lisa M. Frenkel,
  • Connie Celum,
  • Jared M. Baeten,
  • The Partners Demonstration Project Team

DOI
https://doi.org/10.12688/gatesopenres.12752.2
Journal volume & issue
Vol. 1

Abstract

Read online

Background: Pre-exposure prophylaxis (PrEP) can provide high protection against HIV infection and is a recommended intervention for HIV-negative persons with substantial HIV risk. Demonstration projects conducted in diverse settings worldwide illustrate practical examples of how PrEP can be delivered. This manuscript presents estimates of effectiveness and patterns of PrEP use within a two-year demonstration project of PrEP for HIV-negative members of heterosexual HIV serodiscordant couples in East Africa. Methods: The PrEP delivery model integrated PrEP into HIV treatment services, prioritizing PrEP use for HIV-negative partners within serodiscordant couples before and during the first 6 months after the partner living with HIV initiated antiretroviral therapy (ART). We measured PrEP uptake through pharmacy records and adherence to PrEP through medication event monitoring system (MEMS) bottle caps and quantification of tenofovir in plasma among a random sample of participants. We estimated HIV infections prevented using a counterfactual cohort simulated from the placebo arm of a previous PrEP clinical trial. Results: We enrolled 1,010 HIV serodiscordant couples that were naïve to ART and PrEP. Ninety-seven percent of HIV-negative partners initiated PrEP. Objective measures suggest high adherence: 71% of HIV-negative participants took ≥80% of expected doses, as recorded via MEMS, and 81% of plasma samples had tenofovir detected. Four incident HIV infections were observed (incidence rate=0.24 per 100 person-years), a 95% reduction (95% CI 86-98%, p<0.0001) in HIV incidence, relative to estimated HIV incidence for the population in the absence of PrEP integrated into HIV treatment services. Conclusions: PrEP uptake and adherence were high and incident HIV was rare in this PrEP demonstration project for African HIV-negative individuals whose partners were known to be living with HIV. Delivery of PrEP to HIV-negative partners within HIV serodiscordant couples was feasible and should be prioritized for wide-scale implementation.

Keywords